BACKGROUND: Co-morbidity with tuberculosis and HIV is a common cause of mortality in sub-Saharan Africa. In the second Kenya AIDS Indicator Survey, we collected data on knowledge and experience of HIV and tuberculosis, as well as on access to and coverage of relevant treatment services and antiretroviral therapy (ART) in Kenya. METHODS: A national, population-based household survey was conducted from October 2012 to February 2013. Information was collected through household questionnaires, and blood samples were taken for HIV, CD4 cell counts, and HIV viral load testing at a central laboratory. RESULTS: Overall, 13,720 persons aged 15-64 years participated; 96.7% [95% confidence interval (CI): 96.3 to 97.1] had heard of tuberculosis, of whom 2.0% (95% CI: 1.7 to 2.2) reported having prior tuberculosis. Among those with laboratory-confirmed HIV infection, 11.6% (95% CI: 8.9 to 14.3) reported prior tuberculosis. The prevalence of laboratory-confirmed HIV infection in persons reporting prior tuberculosis was 33.2% (95% CI: 26.2 to 40.2) compared to 5.1% (95% CI: 4.5 to 5.8) in persons without prior tuberculosis. Among those in care, coverage of ART for treatment-eligible persons was 100% for those with prior tuberculosis and 88.6% (95% CI: 81.6 to 95.7) for those without. Among all HIV-infected persons, ART coverage among treatment-eligible persons was 86.9% (95% CI: 74.2 to 99.5) for persons with prior tuberculosis and 58.3% (95% CI: 47.6 to 69.0) for those without. CONCLUSIONS: Morbidity from tuberculosis and HIV remain major health challenges in Kenya. Tuberculosis is an important entry point for HIV diagnosis and treatment. Lack of knowledge of HIV serostatus is an obstacle to access to HIV services and timely ART for prevention of HIV transmission and HIV-associated disease, including tuberculosis.
BACKGROUND: Co-morbidity with tuberculosis and HIV is a common cause of mortality in sub-Saharan Africa. In the second Kenya AIDS Indicator Survey, we collected data on knowledge and experience of HIV and tuberculosis, as well as on access to and coverage of relevant treatment services and antiretroviral therapy (ART) in Kenya. METHODS: A national, population-based household survey was conducted from October 2012 to February 2013. Information was collected through household questionnaires, and blood samples were taken for HIV, CD4 cell counts, and HIV viral load testing at a central laboratory. RESULTS: Overall, 13,720 persons aged 15-64 years participated; 96.7% [95% confidence interval (CI): 96.3 to 97.1] had heard of tuberculosis, of whom 2.0% (95% CI: 1.7 to 2.2) reported having prior tuberculosis. Among those with laboratory-confirmed HIV infection, 11.6% (95% CI: 8.9 to 14.3) reported prior tuberculosis. The prevalence of laboratory-confirmed HIV infection in persons reporting prior tuberculosis was 33.2% (95% CI: 26.2 to 40.2) compared to 5.1% (95% CI: 4.5 to 5.8) in persons without prior tuberculosis. Among those in care, coverage of ART for treatment-eligible persons was 100% for those with prior tuberculosis and 88.6% (95% CI: 81.6 to 95.7) for those without. Among all HIV-infectedpersons, ART coverage among treatment-eligible persons was 86.9% (95% CI: 74.2 to 99.5) for persons with prior tuberculosis and 58.3% (95% CI: 47.6 to 69.0) for those without. CONCLUSIONS: Morbidity from tuberculosis and HIV remain major health challenges in Kenya. Tuberculosis is an important entry point for HIV diagnosis and treatment. Lack of knowledge of HIV serostatus is an obstacle to access to HIV services and timely ART for prevention of HIV transmission and HIV-associated disease, including tuberculosis.
Authors: Brian G Williams; Reuben Granich; Kevin M De Cock; Philippe Glaziou; Abhishek Sharma; Christopher Dye Journal: Proc Natl Acad Sci U S A Date: 2010-10-25 Impact factor: 11.205
Authors: E Libamba; S Makombe; A D Harries; R Chimzizi; F M Salaniponi; E J Schouten; R Mpazanje Journal: Int J Tuberc Lung Dis Date: 2005-10 Impact factor: 2.373
Authors: Wanjiru Waruiru; Andrea A Kim; Davies O Kimanga; James Ng'ang'a; Sandra Schwarcz; Lucy Kimondo; Anne Ng'ang'a; Mamo Umuro; Mary Mwangi; James K Ojwang'; William K Maina Journal: J Acquir Immune Defic Syndr Date: 2014-05-01 Impact factor: 3.731
Authors: S B Lucas; A Hounnou; C Peacock; A Beaumel; G Djomand; J M N'Gbichi; K Yeboue; M Hondé; M Diomande; C Giordano Journal: AIDS Date: 1993-12 Impact factor: 4.177
Authors: William K Maina; Andrea A Kim; George W Rutherford; Malayah Harper; Boniface O K'Oyugi; Shahnaaz Sharif; George Kichamu; Nicholas M Muraguri; Willis Akhwale; Kevin M De Cock Journal: J Acquir Immune Defic Syndr Date: 2014-05-01 Impact factor: 3.731
Authors: Muthoni Karanja; Leonard Kingwara; Philip Owiti; Elvis Kirui; Faith Ngari; Richard Kiplimo; Maurice Maina; Enos Masini; Elizabeth Onyango; Catherine Ngugi Journal: PLoS One Date: 2020-12-02 Impact factor: 3.240
Authors: Nikhil Kothegal; Alice Wang; Sasi Jonnalagadda; Adam MacNeil; Elizabeth Radin; Kristin Brown; Owen Mugurungi; Regis Choto; Shirish Balachandra; John H Rogers; Godfrey Musuka; Thokozani Kalua; Michael Odo; Andrew Auld; Laurence Gunde; Evelyn Kim; Danielle Payne; Patrick Lungu; Lloyd Mulenga; Ahmed Saadani Hassani; Tepa Nkumbula; Hetal Patel; Bharat Parekh; Andrew C Voetsch Journal: MMWR Morb Mortal Wkly Rep Date: 2021-03-12 Impact factor: 17.586
Authors: Andrea A Kim; Irene Mukui; Lucy N'gan'ga; Abraham Katana; Dan Koros; Joyce Wamicwe; Kevin M De Cock Journal: PLoS One Date: 2016-03-01 Impact factor: 3.240